Vanjan Inc. is a privately owned
emerging Bio pharmaceutical company
focused on advancing patient care
through commercialization of new
drugs and therapies for the treatment
of Infectious Diseases. Our strategy is
to develop and commercialize products
both independently and in partnership
with other pharmaceutical companies.
We are actively seeking collaborations
from both public and private institutions
that are aligned with our core interests
in advancing Infectious Diseases
patient care by extending the range of
available therapeutic options
read more...
emerging Bio pharmaceutical company
focused on advancing patient care
through commercialization of new
drugs and therapies for the treatment
of Infectious Diseases. Our strategy is
to develop and commercialize products
both independently and in partnership
with other pharmaceutical companies.
We are actively seeking collaborations
from both public and private institutions
that are aligned with our core interests
in advancing Infectious Diseases
patient care by extending the range of
available therapeutic options
read more...
Current Focus Area : Infectious Diseases
Vanjan is currently focused on Infectious Diseases like HIV/TB which are the
problem faced by people globally.
Approximately the total number of people living with HIV has risen from a 8
million in 1990 to nearly 40 million today, and is still growing. Around 63% of
people living with HIV are in sub-Saharan Africa. During 2006 around four million
adults and children became infected with HIV, the virus that causes AIDS. By the
end of the year, an estimated 39.5 million people worldwide were living with
HIV/AIDS. The year also saw around three million deaths from AIDS, despite
recent improvements in access to anti-retro viral treatment. Vanjan is committed
in exploring new treatments and finding solutions for this disease to help people
across the world
Tuberculosis (TB) is primarily an illness of the respiratory system, and is spread
by coughing and sneezing. Each year about 1.6 million people die from this
curable disease. Someone in the world is newly infected with TB bacilli every
second. Overall, one-third of the world's population is currently infected with the
TB bacillus. 5-10% of people who are infected with TB bacilli (but who are not
infected with HIV) become sick or infectious at some time during their life. People
with HIV and TB infection are much more likely to develop TB.
Vanjan is currently focused on Infectious Diseases like HIV/TB which are the
problem faced by people globally.
Approximately the total number of people living with HIV has risen from a 8
million in 1990 to nearly 40 million today, and is still growing. Around 63% of
people living with HIV are in sub-Saharan Africa. During 2006 around four million
adults and children became infected with HIV, the virus that causes AIDS. By the
end of the year, an estimated 39.5 million people worldwide were living with
HIV/AIDS. The year also saw around three million deaths from AIDS, despite
recent improvements in access to anti-retro viral treatment. Vanjan is committed
in exploring new treatments and finding solutions for this disease to help people
across the world
Tuberculosis (TB) is primarily an illness of the respiratory system, and is spread
by coughing and sneezing. Each year about 1.6 million people die from this
curable disease. Someone in the world is newly infected with TB bacilli every
second. Overall, one-third of the world's population is currently infected with the
TB bacillus. 5-10% of people who are infected with TB bacilli (but who are not
infected with HIV) become sick or infectious at some time during their life. People
with HIV and TB infection are much more likely to develop TB.
 | |  | |  | |  | |  | |  |
Home
